Semaglutide

Where the papers sit

84 papers from the last 6 months study semaglutide directly · updated from PubMed 12 Oct 2026

• GLP-1 Receptor Therapies

  GLP-1 receptor agonists are extending from diabetes and obesity care into cardiovascular prevention, neurobiology, and engineered long-acting peptides. Real-world studies repeatedly assess oral semaglutide effectiveness, persistence, safety, and treatment changes. Peptide stabilization, IDE-resistant designs, Fc engagement, and lactam stapling aim to improve durability and CNS stability. Open questions include muscle loss, gastrointestinal transit, financing, and environmental burden.

  27 papers · 32.1%

• Real-World Diabetes and Obesity Care

  Semaglutide research is moving from efficacy trials toward routine diabetes and obesity care, prevention, and treatment access. Multicentre studies track weight, glycaemic control, insulin needs, body composition, quality of life, persistence, and safety across diverse populations. CagriSema, added GIP, and comparisons with tirzepatide broaden combination strategies, while postpartum prevention and adolescent use extend the clinical scope. Price, adherence, and global access remain major practical constraints.

  15 papers · 17.9%

• Semaglutide in MASH Fibrosis

  MASH treatment is moving beyond weight loss toward fibrosis regression, liver-related health utility, and protection from progression to cirrhosis. Semaglutide is being tested in people with MASLD or MASH, including those with HIV, alongside mechanistic work on intrahepatic sinusoidal endothelial GLP-1 receptors. Comparisons with resmetirom and CRV431 examine complementary or divergent effects on fibrosis and hepatocellular carcinoma. Cost-effectiveness and reliable pathology assessment remain important barriers to wider adoption.

  12 papers · 14.3%

• Cardiometabolic Semaglutide Outcomes

  Cardiometabolic benefit is being tested beyond weight loss through endothelial function, hsCRP, cardiovascular events, and kidney outcomes in diabetes, obesity, and established cardiovascular disease. Pooled SELECT, FLOW, and SOUL analyses push evaluation toward integrated cardio-kidney endpoints, while real-world AROS data test external validity. Comparisons with empagliflozin, dapagliflozin, tirzepatide, cagrilintide, and CagriSema, plus withdrawal studies, probe durability and alternatives. Economic analyses increasingly connect clinical benefit with societal value and coverage.

  11 papers · 13.1%

• Medical and Surgical Weight Management

  Obesity care is increasingly comparing semaglutide and tirzepatide with sleeve gastrectomy, lifestyle treatment, and digital weight-loss services. Studies focus on one-year weight loss, persistence, tolerability, access, and patient satisfaction rather than efficacy alone. Semaglutide is also being tested after bariatric surgery and in suboptimal surgical responders, positioning GLP-1 therapy as an adjunct to surgery. The major unresolved issue is which patients gain durable benefit from medication, surgery, or their combination.

  7 papers · 8.3%

• Alternative Peptide Delivery

  Oral and intranasal semaglutide formulations are being developed to overcome peptide degradation and dependence on injections. Enteric ionic liquids, nanofibers, silk nanoparticles, and thermoresponsive PNPHO carriers target absorption and controlled exposure. Clinical exposure is being linked to glycaemic response, weight loss, and gastrointestinal tolerability. The field remains formulation-focused, with effective bioavailability and reproducible delivery still open questions.

  7 papers · 8.3%

• Cardiovascular and Kidney Outcomes

  GLP-1 receptor agonists are being compared with and combined with SGLT2 inhibitors for cardiovascular, kidney, and glycaemic outcomes in type 2 diabetes. Studies examine myocardial infarction, ischemic stroke, atherosclerotic disease, atrial fibrillation, and early diabetic kidney disease. Real-world comparisons include oral semaglutide, canagliflozin, and other noninsulin therapies, while seizure risk remains a separate safety question. The central issue is comparative and combination effectiveness rather than weight loss alone.

  5 papers · 6%